Terms: = Sarcomas AND DCTN1, DAP-150, 1639, ENSG00000204843, Q14203, P135, DP-150 AND Treatment
7 results:
1. Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model.
Brozovich AA; Lenna S; Brenner C; Serpelloni S; Paradiso F; McCulloch P; Yustein JT; Weiner B; Taraballi F
ACS Biomater Sci Eng; 2024 Mar; 10(3):1646-1660. PubMed ID: 38350651
[TBL] [Abstract] [Full Text] [Related]
2. Multidisciplinary management of adolescents and young adults (AYA) sarcoma: A successful effort of an adult high-volume cancer center.
Bertuzzi AF; Grimaudo MS; Laffi A; Giordano L; Gennaro N; Cariboni U; Siracusano LV; Quagliuolo V; Colombo P; Federico D; Renne SL; Specchia C; Cananzi F; Marrari A; Navarria P; Daolio PA; Bastoni S; Santoro A
Cancer Med; 2023 Aug; 12(15):16254-16263. PubMed ID: 37366268
[TBL] [Abstract] [Full Text] [Related]
3. The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis.
van Weelden WJ; Birkendahl PB; Lalisang RI; IntHout J; Kruitwagen RFPM; Romano A; Pijnenborg JMA
BJOG; 2023 Jan; 130(2):143-152. PubMed ID: 36264251
[TBL] [Abstract] [Full Text] [Related]
4. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract] [Full Text] [Related]
5. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
[TBL] [Abstract] [Full Text] [Related]
6. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract] [Full Text] [Related]
7. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring dctn1-ALK fusion.
Subbiah V; McMahon C; Patel S; Zinner R; Silva EG; Elvin JA; Subbiah IM; Ohaji C; Ganeshan DM; Anand D; Levenback CF; Berry J; Brennan T; Chmielecki J; Chalmers ZR; Mayfield J; Miller VA; Stephens PJ; Ross JS; Ali SM
J Hematol Oncol; 2015 Jun; 8():66. PubMed ID: 26062823
[TBL] [Abstract] [Full Text] [Related]
